Anti-epileptic Drugs for Pediatrics Market

Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.

Anti-epileptic Drugs for Pediatrics Market contains market size and forecasts of Anti-epileptic Drugs for Pediatrics in global, including the following market information:

Global Anti-epileptic Drugs for Pediatrics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Anti-epileptic Drugs for Pediatrics Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Anti-epileptic Drugs for Pediatrics companies in 2021 (%)

The global Anti-epileptic Drugs for Pediatrics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

1st Generation Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Anti-epileptic Drugs for Pediatrics include Mylan N.V, Cephalon, Inc, GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc, Sanofi S.A, UCB Pharma Limited and Sunovion Pharmaceuticals Limited, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Anti-epileptic Drugs for Pediatrics manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Anti-epileptic Drugs for Pediatrics Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti-epileptic Drugs for Pediatrics Market Segment Percentages, by Type, 2021 (%)

1st Generation

2nd Generation

3rd Generation

Global Anti-epileptic Drugs for Pediatrics Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti-epileptic Drugs for Pediatrics Market Segment Percentages, by Application, 2021 (%)

Hospitals

Retail Pharmacies

Online Pharmacies

Global Anti-epileptic Drugs for Pediatrics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti-epileptic Drugs for Pediatrics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Anti-epileptic Drugs for Pediatrics revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Anti-epileptic Drugs for Pediatrics revenues share in global market, 2021 (%)

Key companies Anti-epileptic Drugs for Pediatrics sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Anti-epileptic Drugs for Pediatrics sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Mylan N.V

Cephalon, Inc

GlaxoSmithKline plc

Janssen Pharmaceuticals

Novartis AG

Pfizer, Inc

Sanofi S.A

UCB Pharma Limited

Sunovion Pharmaceuticals Limited

Valeant Pharmaceuticals International, Inc

Zogenix

GW Pharmaceuticals

Insys

Zynerba